EGFR and central nervous system cancer: The ROC analysis showed that R2’ was able to differentiate EGFR amplification status in treatment-naïve IDH wild-type gliomas with a threshold of 5.71 s−1 (Figure 6e; AUC 0.71, sensitivity 66.7%, specificity 76.9%, accuracy 73.7%).